NCT07578363 An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
| NCT ID | NCT07578363 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Alcon Research |
| Condition | Ocular Hyperemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 178 participants |
| Start Date | 2026-09-27 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 178 participants in total. It began in 2026-09-27 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.
Eligibility Criteria
Key Inclusion Criteria: * Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form. * Willing and able to follow all instructions and attend all study visits. * History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion. * Baseline ocular redness score of 0.5 unit or higher in at least one eye at Visit 1 and greater than 1 unit on a 5-point scale in both eyes prior to randomization at Visit 2. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol. * Ocular surgical interventions within 6 months prior to Visit 1 or during the study. * Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters. * Use of prohibited medications, devices, or treatments as specified in the protocol. * Out of range vital signs (blood pressure and/or pulse rate) as defined in the study protocol. * Abnormal intraocular pressure. * Other protocol-defined exclusion criteria may apply.
Contact & Investigator
Clinical Trial Lead, Pharma
STUDY DIRECTOR
Alcon Research, LLC
Frequently Asked Questions
Who can join the NCT07578363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ocular Hyperemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07578363 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 178 participants.
Is NCT07578363 currently recruiting?
Yes, NCT07578363 is actively recruiting participants. Contact the research team at alcon.medinfo@alcon.com for enrollment information.
Where is the NCT07578363 trial being conducted?
This trial is being conducted at Northbrook, United States, Garner, United States, Shelby, United States, Memphis, United States and 1 additional location.
Who is sponsoring the NCT07578363 clinical trial?
NCT07578363 is sponsored by Alcon Research. The principal investigator is Clinical Trial Lead, Pharma at Alcon Research, LLC. The trial plans to enroll 178 participants.